Teva Pharmaceutical Industries (TEVA) Income towards Parent Company (2016 - 2025)
Teva Pharmaceutical Industries' Income towards Parent Company history spans 10 years, with the latest figure at $466.0 million for Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company rose 265.25% year-over-year to $466.0 million, compared with a TTM value of $466.0 million through Dec 2025, up 265.25%, and an annual FY2025 reading of $1.4 billion, up 171.12% over the prior year.
- Income towards Parent Company for Q4 2025 was $466.0 million at Teva Pharmaceutical Industries, up from $428.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $466.0 million in Q4 2025, with the low at -$2.1 billion in Q4 2022.
- Average Income towards Parent Company over 5 years is -$691.9 million, with a median of -$699.5 million recorded in 2022.
- Year-over-year, Income towards Parent Company tumbled 111.53% in 2022 and then skyrocketed 265.25% in 2025.
- Tracing TEVA's Income towards Parent Company over 5 years: stood at -$1.1 billion in 2021, then crashed by 90.51% to -$2.1 billion in 2022, then surged by 92.76% to -$154.0 million in 2023, then plummeted by 83.12% to -$282.0 million in 2024, then skyrocketed by 265.25% to $466.0 million in 2025.
- Per Business Quant, the three most recent readings for TEVA's Income towards Parent Company are $466.0 million (Q4 2025), $428.0 million (Q3 2025), and $274.0 million (Q2 2025).